Enveric Biosciences Inc Stock Price, News & Analysis

Enveric Biosciences (NASDAQ: ENVB) announced issuance of its 23rd U.S. patent from the USPTO, U.S. Patent No. 12,428,408, titled “Fused Heterocyclic Mescaline Derivatives.”

The patent covers a unique series of neuroplastogenic small-molecule compounds designed to target key serotonin receptors and promote neuroplasticity, expanding Enveric’s intellectual property footprint and supporting potential pipeline expansion for treatments of psychiatric and neurological disorders.

Enveric Biosciences (NASDAQ: ENVB) said it retained Fish and Richardson to defend U.S. Patent No. 12,138,276 (the ‘276 patent) after a Post‑Grant Review petition was filed by Gilgamesh Pharmaceuticals on claims that appear relevant to Bretisilocin (GM‑2505), which AbbVie agreed to acquire on August 25, 2025 in a definitive transaction valued at up to $1.2 billion. The ‘276 family includes one issued U.S. patent, additional pending U.S. and international applications, and is separate from Enveric’s EB‑003 patent families.

Enveric reported an intellectual property portfolio of 26 issued U.S. patents and 60 pending national and international applications, multiple programs advancing toward clinical development, and out‑license agreements with potential aggregate milestones of up to $205 million plus royalties.

Enveric Biosciences (NASDAQ: ENVB) announced on October 14, 2025 that its Board authorized the Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities.

Any DAT opportunities would require further review and approval by the full Board. The company said this initiative is intended to enhance shareholder value and support long-term growth while it remains committed to advancing its core biotechnology programs. The company will provide updates as developments occur.

Enveric Biosciences (NASDAQ: ENVB) has achieved significant chemistry, manufacturing, and controls (CMC) milestones for its lead candidate EB-003, advancing towards first-in-human clinical trials. The company has successfully: produced a pharmaceutically compatible salt form, developed a scalable synthetic route, and manufactured a 1-kilogram batch of EB-003.

EB-003 is a novel small molecule with dual agonism at 5-HT1B and 5-HT2A receptors, targeting neuropsychiatric conditions. These manufacturing achievements are crucial for supporting upcoming Investigational New Drug (IND) application activities, including GLP toxicology studies and drug product formulation work.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, has announced the closing of previously announced warrant exercises, generating $2.2 million in gross proceeds. The transaction involved the exercise of series A and B warrants at a reduced price of $0.915 per share, down from the original $3.00 per share.

In exchange for the immediate cash exercise, Enveric issued new unregistered warrants: Series C warrants for up to 2,424,998 shares (5-year term) and Series D warrants for up to 2,424,998 shares (18-month term), both with a $0.915 exercise price. The company plans to use proceeds for product development, working capital, and general corporate purposes.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, has announced warrant exercises that will generate $2.2 million in gross proceeds. The company secured agreements for the immediate exercise of series A and B warrants totaling 2,424,998 shares at a reduced price of $0.915 per share, down from the original $3.00 exercise price.

In exchange for the immediate cash exercise, Enveric will issue new unregistered series C and D warrants, each allowing the purchase of up to 2,424,998 shares at $0.915 per share. The series C warrants will have a 5-year term, while series D warrants will expire in 18 months. The company plans to use the proceeds for product development, working capital, and general corporate purposes.

Enveric Biosciences (NASDAQ: ENVB) announced the publication of two significant peer-reviewed research papers showcasing innovative bioproduction methods for neuropsychiatric drug discovery. The first paper in ACS Chemical Biology details the creation of 279 tryptamine derivatives, including 17 novel compounds showing interaction with melatonin and serotonin receptors. The second paper in BioDesign Research presents the first-ever bioproduction method for MDMA and related compounds using engineered yeast.

The company's lead candidate EB-003, manufactured through traditional synthetic chemistry, represents a novel class of neuroplastogens targeting both 5-HT₂A and 5-HT₁B receptors. Enveric plans to submit an Investigational New Drug (IND) application with first-in-human studies expected in 2026.

Enveric Biosciences (NASDAQ: ENVB) has received FDA response regarding its pre-IND Type B meeting request for EB-003, its lead neuroplastogenic program. The FDA recommended that Enveric proceed directly to submitting its Investigational New Drug (IND) application, suggesting the company's development strategy is sufficiently advanced.

The company plans to file the IND application for EB-003 in early 2026. EB-003 is designed as a dual-acting compound targeting depression and anxiety through durable neuroplastic changes without hallucinogenic effects. Enveric's intellectual property portfolio includes 26 issued U.S. patents and 60 pending national and international applications.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Joseph Tucker, Ph.D., will deliver a virtual presentation on September 8, 2025, at 7:00 AM ET.

The presentation will highlight the company's pipeline of therapeutics for depression, anxiety, and addiction disorders, featuring their lead candidate EB-003. This compound is designed to provide neuroplastogenic benefits while minimizing hallucinatory effects, with a dual-targeting mechanism showing partial agonism at 5-HT₂A receptor and agonism at 5-HT₁B receptor. Dr. Tucker will also conduct one-on-one meetings with investors and potential partners.